Small-cell Lung Cancer: Clinical Trials

52 trials for Small-cell Lung Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 recruiting, 11 completed, 11 unknown, 9 terminated. 52 Phase 2, 14 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 252Recruiting 12, Completed 11, Unknown 11, Terminated 9, Active not recruiting 7, Enrolling by invitation 1, Withdrawn 1
Phase 114Completed 4, Active not recruiting 3, Recruiting 3, Terminated 3, Unknown 1
Phase 31Completed 1

Follow Small-cell Lung Cancer: new trials by email Literature Review of Small-cell Lung Cancer trials Research Report on Small-cell Lung Cancer

Trials (filtered) newest first · largest first

All 52 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
Cirtuvivint, Irinotecan - Small-cell Lung Cancer, Small Cell Lung Carcinoma
Phase 1 / Phase 2RecruitingWashington University School of Medicine422025-12-182026-08-12
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
IDE849, durvalumab, IDE161 - Small-cell Lung Cancer, Neuroendocrine Carcinomas
Phase 1 / Phase 2RecruitingIDEAYA Biosciences2622025-10-142026-07-09
Phase 2 Study of Fingolimod in Lung Cancers
Fingolimod 0.5 milligram (mg) [Gilenya] - Non Small Cell Lung Cancer, Small-cell Lung Cancer
Phase 2RecruitingMedical University of South Carolina382025-05-012026-03-30
Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status
Tarlatamab - Small-cell Lung Cancer
Phase 2RecruitingAIO-Studien-gGmbH572025-01-012026-10-26
A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC
ivonescimab, irinotecan liposome - Small-cell Lung Cancer
Phase 2CompletedZhejiang Cancer Hospital602024-10-162026-08-27
Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic
Intrathecal Pemetrexed - Small-cell Lung Cancer
Phase 2UnknownHunan Province Tumor Hospital802024-10-012024-09-19
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide - Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
Phase 2Active not recruitingBioNTech SE1102024-08-052026-11-06
Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer
hypofractionated radiotherapy with immunotherapy - Small-cell Lung Cancer
Phase 1 / Phase 2RecruitingAnhui Provincial Hospital452024-07-012024-09-19
Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study
Teniposide, Etoposide, serplulimab - Small-cell Lung Cancer
Phase 2RecruitingSun Yat-sen University902024-02-012026-05-13
Chemotherapy-immunotherapy-based Split-course Adaptive Hypofractionated Radiotherapy for Extensive-stage SCLC
split-course adaptive hypofractionated radiotherapy - Small-cell Lung Cancer
Phase 2Enrolling by invitationFujian Medical University Union Hospital352023-12-262025-02-10
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
XNW5004, KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection - Carcinoma, Squamous Cell Carcinoma of Head and Neck
Phase 1 / Phase 2TerminatedEvopoint Biosciences Inc.122023-09-202026-07-23
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment
Serplulimab, SOC - Small-cell Lung Cancer
Phase 2Active not recruitingGuangdong Association of Clinical Trials662023-07-072026-07-28
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine - Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer
Phase 2TerminatedMacroGenics1922023-06-132026-02-09
JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
JS201 combine with Lenvatinib - Small-cell Lung Cancer
Phase 2UnknownHunan Province Tumor Hospital302023-06-012024-09-19
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
ADI-PEG 20, Gemcitabine, Docetaxel - Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
Phase 1 / Phase 2TerminatedWashington University School of Medicine312023-04-052026-07-27
EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer
EP0057, Olaparib tablets - Gastric Cancer, Small-cell Lung Cancer
Phase 2WithdrawnEllipses Pharma2023-04-012023-06-12
A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer
HLX07, HLX10, carboplatin and etoposide - Small-cell Lung Cancer
Phase 2UnknownShanghai Henlius Biotech202023-03-292022-05-04
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Carboplatin, Pemetrexed, Paclitaxel - Lung Cancer, Small-cell Lung Cancer
Phase 2RecruitingFox Chase Cancer Center2802023-02-222026-05-22
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
Iadademstat, Paclitaxel - Small-cell Lung Cancer, Neuroendocrine Carcinoma
Phase 2TerminatedFox Chase Cancer Center202022-12-212025-07-30
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
JK08, Pembrolizumab, Lenvatinib Pill - Cancer, Tumor, Solid
Phase 1 / Phase 2Active not recruitingSalubris Biotherapeutics Inc2632022-10-172024-10-15

Showing 20 of 52. Sign in to see all of them.

Narrower conditions

Small Cell Lung Carcinoma (52)  ·  Carcinoma, Non-Small-Cell Lung (8)  ·  Lung Neoplasms (7)  ·  Carcinoma, Neuroendocrine (4)  ·  Prostatic Neoplasms (4)  ·  Squamous Cell Carcinoma of Head and Neck (4)  ·  Stomach Neoplasms (4)  ·  Triple Negative Breast Neoplasms (4)  ·  Carcinoma, Transitional Cell (3)  ·  Thyroid Neoplasms (3)  ·  Anus Neoplasms (2)  ·  Brain Neoplasms (2)  ·  Carcinoma (2)  ·  Carcinoma, Ovarian Epithelial (2)  ·  Cholangiocarcinoma (2)

Broader conditions

Bronchial Neoplasms (52)  ·  Carcinoma, Bronchogenic (52)  ·  Lung Diseases (52)  ·  Neoplasms by Site (52)  ·  Respiratory Tract Diseases (52)  ·  Respiratory Tract Neoplasms (52)  ·  Thoracic Neoplasms (52)  ·  Neoplasms (50)  ·  Lung Neoplasms (45)  ·  Neoplasms by Histologic Type (13)  ·  Neoplasms, Glandular and Epithelial (11)  ·  Carcinoma (9)  ·  Genital Diseases (8)  ·  Urogenital Diseases (8)  ·  Urogenital Neoplasms (8)

Interventions

Etoposide (16)  ·  Carboplatin (15)  ·  Cisplatin (5)  ·  atezolizumab (5)  ·  durvalumab (5)  ·  Radiosurgery (4)  ·  pembrolizumab (4)  ·  Irinotecan (3)  ·  Paclitaxel (3)  ·  Topotecan (3)  ·  apatinib (3)  ·  Docetaxel (2)  ·  Gemcitabine (2)  ·  Nivolumab (2)  ·  PM 01183 (2)

Sponsors

Shanghai Pulmonary Hospital, Shanghai, China (3)  ·  Fox Chase Cancer Center (2)  ·  Hunan Province Tumor Hospital (2)  ·  TransThera Sciences (Nanjing), Inc. (2)  ·  Washington University School of Medicine (2)  ·  AIO-Studien-gGmbH (1)  ·  Anhui Provincial Hospital (1)  ·  AstraZeneca (1)  ·  BioNTech SE (1)  ·  Brian Henick, MD (1)  ·  Case Comprehensive Cancer Center (1)  ·  Chinese Academy of Medical Sciences (1)  ·  Dwight Owen (1)  ·  EMD Serono Research & Development Institute, Inc. (1)  ·  Ellipses Pharma (1)

Countries

United States (27)  ·  China (23)  ·  South Korea (6)  ·  Spain (5)  ·  Australia (3)  ·  Belgium (3)  ·  France (3)  ·  Germany (2)  ·  Italy (2)  ·  Poland (2)  ·  Turkey (Türkiye) (2)  ·  United Kingdom (2)  ·  Canada (1)  ·  Chile (1)  ·  Denmark (1)

Top investigators

ShengFa Su, PhD,MD (2)  ·  Afshin Dowlati, MD (1)  ·  Anish Thomas, MD (1)  ·  Ashish Saxena, MD (1)  ·  Brian Henick, MD (1)  ·  Christine Auberle, M.D. (1)  ·  Christine Bestvina, MD (1)  ·  Dwight Owen, MD, MS (1)  ·  Jared Weiss, MD (1)  ·  Jeffrey Clarke, MD (1)  ·  Jin-Ji Yang, PhD (1)  ·  Jordi Rodon Ahnert, MD, PhD (1)  ·  Julia Judd, DO (1)  ·  Kathryn Beckermann, MD (1)

Results publications

PMID 10561263, PMID 25230595, PMID 30280641, PMID 33166719, PMID 33234490, PMID 33446664, PMID 36727741, PMID 36907793, PMID 37977903, PMID 39462179, PMID 39941812, PMID 40210967, PMID 40481574

NIH funding

2017 (1), 2025 (1), R01CA273216 (1)